Cartesian Therapeutics Inc (NAS:RNAC)
$ 35.64 -0.36 (-1%) Market Cap: 634.25 Mil Enterprise Value: 534.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Selecta Biosciences, Inc. - Special Call Transcript

Sep 30, 2020 / 09:30PM GMT
Release Date Price: $74.4 (-3.12%)
Operator

Good afternoon, and welcome to the Selecta Biosciences Phase II COMPARE Conference Call. (Operator Instructions) For opening remarks, I would like to introduce Brad Dahms, Chief Financial Officer of Selecta. Please go ahead, sir.

Bradford D. Dahms
Selecta Biosciences, Inc. - CFO, Principal Financial Officer & Principal Accounting Officer

Thank you, and good afternoon. During this call, we will discuss top line results from the Phase II COMPARE study of SEL-212, a novel treatment for chronic refractory gout versus pegloticase. The press release reporting the results and the presentation that Carsten and Peter will walk through are available in the Investors & Media section of our website, www.selectabio.com.

Joining me today are Carsten Brunn, our President and Chief Executive Officer; and Dr. Peter G. Traber, our Chief Medical Officer. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot